AR051290A1 - Derivados de hidantoina sustituidas - Google Patents

Derivados de hidantoina sustituidas

Info

Publication number
AR051290A1
AR051290A1 ARP050103857A ARP050103857A AR051290A1 AR 051290 A1 AR051290 A1 AR 051290A1 AR P050103857 A ARP050103857 A AR P050103857A AR P050103857 A ARP050103857 A AR P050103857A AR 051290 A1 AR051290 A1 AR 051290A1
Authority
AR
Argentina
Prior art keywords
substituted
group
heteroaryl
unsubstituted
lower alkoxy
Prior art date
Application number
ARP050103857A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR051290A1 publication Critical patent/AR051290A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a derivados de hidantoina sustituidas, composiciones farmacéuticas que los contienen y usos para el tratamiento de enfermedades tales como el cáncer, los trastornos cognitivos y del SNC y enfermedades inflamatorias y autoinmunes. Reivindicacion 1: Un compuesto de la formula (1) en la que R1 es COR5; R2 es H; R3 se elige entre el grupo formado por alquilo sustituido o sin sustituir, alquenilo o alquinilo, cicloalquilo y heterociclo, arilo o heteroarilo sustituidos o sin sustituir; R4 se elige entre el grupo formado por arilo y heteroarilo sustituido o sin sustituir; R5 se elige entre el grupo formado por alquilo inferior, alcoxi inferior o amina sustituidos con independencia entre sí por un sustituyente elegido entre el grupo formado por H, alquilo inferior y alcoxi inferior; opcionalmente en forma de sus racematos, sus enantiomeros, sus diastereomeros o mezclas de los mismos, o las sales, ésteres o profármacos farmacéuticamente aceptables de los mismos.
ARP050103857A 2004-09-17 2005-09-15 Derivados de hidantoina sustituidas AR051290A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61065504P 2004-09-17 2004-09-17

Publications (1)

Publication Number Publication Date
AR051290A1 true AR051290A1 (es) 2007-01-03

Family

ID=35447646

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103857A AR051290A1 (es) 2004-09-17 2005-09-15 Derivados de hidantoina sustituidas

Country Status (16)

Country Link
US (1) US7371869B2 (es)
EP (1) EP1791837B1 (es)
JP (1) JP4685873B2 (es)
KR (1) KR100869681B1 (es)
CN (1) CN101023079B (es)
AR (1) AR051290A1 (es)
AT (1) ATE440097T1 (es)
AU (1) AU2005284293B2 (es)
BR (1) BRPI0515371A (es)
CA (1) CA2579130A1 (es)
DE (1) DE602005016127D1 (es)
ES (1) ES2329264T3 (es)
MX (1) MX2007003166A (es)
RU (1) RU2393156C2 (es)
TW (1) TW200621766A (es)
WO (1) WO2006029862A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
ATE551336T1 (de) * 2007-08-16 2012-04-15 Hoffmann La Roche Substituierte hydantoine
JP2011506533A (ja) * 2007-12-20 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー Ｍｅｋキナーゼ阻害剤としての置換ヒダントイン
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
CN102656142A (zh) 2009-10-21 2012-09-05 拜耳制药股份公司 取代的苯磺酰胺
US20120263714A1 (en) 2009-10-21 2012-10-18 Bayer Intellectual Property Gmbh Substituted halophenoxybenzamide derivatives
EP3689347A1 (en) 2009-11-02 2020-08-05 Ariagen, Inc. Ite for cancer intervention and eradication
US10632106B2 (en) 2009-11-02 2020-04-28 Ariagen, Inc. Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
EP3028699B1 (en) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
ES2714875T3 (es) 2010-03-09 2019-05-30 Dana Farber Cancer Inst Inc Métodos de diagnóstico y tratamiento del cáncer en pacientes que presentan o desarrollan resistencia a una primera terapia del cáncer
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
KR101472175B1 (ko) * 2012-02-17 2014-12-15 중앙대학교 산학협력단 신규한 2-아미노티아졸 유도체 및 이를 유효성분으로 포함하는 항암용 조성물
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN107001350B (zh) 2014-09-12 2021-04-09 阿里根公司 2-(1’h-吲哚-3’-羰基)-噻唑-4-羧酸甲酯及其结构类似物的有效且可扩展的合成
RU2605091C2 (ru) * 2015-05-12 2016-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития" 2-амино-1-арил-5-(3,3-диметил-2-оксобутилиден)-4-оксо-n-(тиазол-5-ил)-4,5-дигидро-1н-пиррол-3-карбоксамиды, проявляющие противоопухолевую и антирадикальную активность, способ их получения и фармацевтическая композиция на их основе
CN108239083B (zh) 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
RS63603B1 (sr) 2017-04-18 2022-10-31 Shanghai Fochon Pharmaceutical Co Ltd Sredstva za indukciju apoptoze
JP2021503498A (ja) 2017-11-20 2021-02-12 アリアジェン，インコーポレイテッド アリール炭化水素受容体（ａｈｒ）調節剤としてのインドール化合物
US10555558B2 (en) 2017-12-29 2020-02-11 Rai Strategic Holdings, Inc. Aerosol delivery device providing flavor control
JP2022528977A (ja) 2019-04-15 2022-06-16 アリアジェン，インコーポレイテッド キラルインドール化合物およびその使用
WO2021027722A1 (zh) * 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001426A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
KR19990012061A (ko) 1997-07-26 1999-02-25 성재갑 파네실 전이효소 저해제로 유용한 하이덴토인 유도체
EP1280801B1 (en) 2000-05-03 2005-09-07 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
JP2004534857A (ja) * 2001-07-19 2004-11-18 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−チアゾール誘導体、それらの製造のための方法及び抗癌剤としてのそれらの使用
ES2313389T3 (es) * 2004-08-17 2009-03-01 F. Hoffmann-La Roche Ag Hidantoinas sustituidas.

Also Published As

Publication number Publication date
WO2006029862A1 (en) 2006-03-23
DE602005016127D1 (de) 2009-10-01
KR100869681B1 (ko) 2008-11-21
JP2008513397A (ja) 2008-05-01
CA2579130A1 (en) 2006-03-23
RU2007114125A (ru) 2008-10-27
JP4685873B2 (ja) 2011-05-18
EP1791837B1 (en) 2009-08-19
RU2393156C2 (ru) 2010-06-27
US20060063814A1 (en) 2006-03-23
TW200621766A (en) 2006-07-01
ATE440097T1 (de) 2009-09-15
ES2329264T3 (es) 2009-11-24
US7371869B2 (en) 2008-05-13
CN101023079B (zh) 2010-05-05
AU2005284293A1 (en) 2006-03-23
MX2007003166A (es) 2007-05-15
KR20070043895A (ko) 2007-04-25
BRPI0515371A (pt) 2008-07-22
AU2005284293B2 (en) 2011-10-06
CN101023079A (zh) 2007-08-22
EP1791837A1 (en) 2007-06-06

Similar Documents

Publication Publication Date Title
AR051290A1 (es) Derivados de hidantoina sustituidas
AR050297A1 (es) Hidantoinas sustituidas
ES2512491T3 (es) Derivados de la piridina pirazolo como inhibidores de la NADPH oxidasa
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR062387A2 (es) El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
AR040476A1 (es) N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina)
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
PE20181272A1 (es) Heterociclilaminas como inhibidores de pi3k
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR073406A1 (es) Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer.
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR070234A1 (es) Compuestos que comprenden un grupo ciclobutoxi
AR063454A1 (es) Derivados acetamida de diazepan como inhibidores selectivos de 11 beta - hsd1. procesos de obtencion y composiciones farmaceuticas.
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure